The startup develops a biocell portfolio that utilizes advanced cell therapies to differentiate between cancerous and healthy cells, targeting treatment for inflammatory conditions, autoimmune diseases, and communicable diseases. By enabling precise patient-specific therapies, the company aims to enhance treatment accessibility and affordability.
Funding
$13.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of cell and gene therapies faces significant hurdles, including the need for specialized expertise and substantial upfront funding to translate scientific ideas into clinical practice. Many promising innovations fail to progress from proven hypotheses to clinical adoption due to these challenges.
Solution
Takura is a biopharma company developer focused on cell and gene therapies, dedicated to translating scientific research into clinical applications. They identify and nurture early-stage biotech companies, providing them with the necessary resources and expertise to navigate the complexities of bringing novel therapies to market. Takura's approach involves founding, funding, and building companies focused on areas like Mesenchymal Stromal Cells (MSCs) and T-cell Immunotherapy. By providing a platform of ATMP specialists, entrepreneurs, and investors, Takura accelerates the development and accessibility of advanced therapies for a range of diseases.
Target Audience
Takura's primary focus is on patients with inflammatory conditions, autoimmune diseases, communicable diseases, and cancer, as well as biotech companies developing cell and gene therapies.
Features
- Focus on cell-based immunotherapies, particularly Tumor Infiltrating Lymphocytes (TILs) for solid tumor cancers.
- Development of Mesenchymal Stromal Cell (MSC) based cell therapies for Acute Respiratory Distress Syndrome (ARDS) and neurodegenerative Alzheimer’s Disease (AD).
- GMP production of high-quality Mesenchymal Stem Cells (MSC) to make them available at scale.
- A network of ATMP specialists, entrepreneurs, and investors.